Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxic epidermal necrolysis: does immunoglobulin make a difference?

K M Brown1, G M Silver, M Halerz

  • 1Department of Surgery, Loyola University Medical Center, Maywood, Illinois 60153, USA.

The Journal of Burn Care & Rehabilitation
|January 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Propensity score analysis of non-anatomical <i>versus</i> anatomical resection of colorectal liver metastases.

BJS open·2019
Same author

Age-related immune responses after burn and inhalation injury are associated with altered clinical outcomes.

Experimental gerontology·2017
Same author

Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia.

Surgery·2017
Same author

Terminal Maturation of Orthochromatic Erythroblasts Is Impaired in Burn Patients.

Journal of burn care & research : official publication of the American Burn Association·2017
Same author

Cutaneous Burn Injury Promotes Shifts in the Bacterial Microbiome in Autologous Donor Skin: Implications for Skin Grafting Outcomes.

Shock (Augusta, Ga.)·2017
Same author

Improving Nutritional Support of Burn Service Patients by Increasing the Number of Days When 100% of Prescribed Formula Is Given.

Journal of burn care & research : official publication of the American Burn Association·2017

Immunoglobulin (Ig) therapy did not improve outcomes for patients with toxic epidermal necrolysis (TEN). This study found no significant reduction in mortality or length of stay, suggesting Ig therapy may not be beneficial for TEN treatment.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Toxic epidermal necrolysis (TEN) is a severe, life-threatening mucocutaneous reaction.
  • Fas ligand-mediated keratinocyte apoptosis is implicated in TEN pathogenesis.
  • Immunoglobulin (Ig) therapy is hypothesized to block Fas ligand signaling, potentially mitigating TEN severity.

Purpose of the Study:

  • To evaluate the efficacy of immunoglobulin (Ig) therapy in treating patients with toxic epidermal necrolysis (TEN).
  • To analyze outcome data, including mortality and length of stay, comparing TEN patients treated with and without Ig therapy.
  • To assess the impact of Ig therapy across different severity levels of TEN using the SCORTEN score.

Main Methods:

  • Retrospective chart review of TEN patients treated at a single burn center since 1997.

Related Experiment Videos

  • Comparison of outcomes between a historical cohort (no-Ig group) and patients treated with Ig therapy after January 2000.
  • Collection and analysis of SCORTEN severity scores, length of stay (LOS), and discharge status for all patients.

    • Main Results:

    • Overall mortality was 28.6% in the no-Ig group and 41.7% in the Ig group.
    • No significant differences were observed in age, TBSA slough, or average SCORTEN scores between the groups.
    • Patients treated with Ig had a longer overall length of stay and longer LOS for survivors.

    Conclusions:

    • This study did not find significant improvement in mortality for TEN patients treated with Ig therapy.
    • The data suggest that Ig therapy may not be beneficial and could potentially be detrimental in TEN management.
    • Further investigation via a multicenter, prospective, double-blinded randomized trial is urgently needed to determine the true efficacy and safety of Ig therapy for TEN.